Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis
Wen S, Jing W, Zhang T, Zong Z, Xue Y, Shang Y, Wang F, Huang H, et al. (10 authors)
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2019-04
Abstract
Delamanid exhibited greater in vitro potency than pretomanid against multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB) isolates. The pretomanid minimum inhibitory concentration (MIC) values of four MDR-TB isolates were found to be resistant to delamanid ranging from 0.031 to 0.063 mg/L. A novel nonsynonymous mutation within the fbiA gene (Glu249Lys) may be contributing to high-level resistance to delamanid and pretomanid in Mycobacterium tuberculosis.
MeSH terms
- Mycobacterium tuberculosis
- Tuberculosis, Multidrug-Resistant
- Nitroimidazoles
- Bacterial Proteins
- Antitubercular Agents
- Microbial Sensitivity Tests
- Drug Resistance, Multiple, Bacterial
- Mutation
- Extensively Drug-Resistant Tuberculosis